Literature DB >> 22920931

Evaluation of serological markers to monitor the disease status of Indian post kala-azar dermal leishmaniasis.

Debanjan Mukhopadhyay1, Nilay Kanti Das, Sritama De Sarkar, Alak Manna, Dwijendra Nath Ganguly, Joyashree Nath Barbhuiya, Arup K Maitra, Avijit Hazra, Mitali Chatterjee.   

Abstract

Post kala-azar dermal leishmaniasis (PKDL), a dermal sequel of visceral leishmaniasis presents with macular or polymorphic lesions. As immunological variations between these two forms have not been delineated, we evaluated levels of antileishmanial total Ig, IgG and its subclasses, IgM, IgE, IgG avidity, cytokines IL-10, IL-4, IL-13 and expression of CD19. The levels of Ig and IgG in polymorphic PKDL were higher than macular PKDL, while significant curtailment in levels of Ig, IgM and IgG following treatment was evident only in polymorphic PKDL. With regard to IgG subclasses, IgG1 and IgG3 were significantly raised in polymorphic PKDL, whereas in macular PKDL only IgG1 was elevated; treatment decreased levels of IgG1, IgG2 and IgG3 only in polymorphic PKDL; IgE levels were raised in both groups but no marked alterations occurred following treatment. The avidity of IgG was higher in polymorphic PKDL and correlated with duration of disease. IL-10 was higher in polymorphic PKDL and decreased significantly after treatment, whereas in macular PKDL IL-4 predominated. Taken together, in PKDL the humoral immune response was greater in the polymorphic variant than the macular form suggesting that serological markers may have a role in monitoring polymorphic PKDL.
Copyright © 2012 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22920931     DOI: 10.1016/j.trstmh.2012.07.005

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  15 in total

Review 1.  Systematic review of biomarkers to monitor therapeutic response in leishmaniasis.

Authors:  Anke E Kip; Manica Balasegaram; Jos H Beijnen; Jan H M Schellens; Peter J de Vries; Thomas P C Dorlo
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

2.  Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.

Authors:  Sakib Burza; Prabhat Kumar Sinha; Raman Mahajan; Marta González Sanz; María Angeles Lima; Gaurab Mitra; Neena Verma; Pradeep Das
Journal:  PLoS Negl Trop Dis       Date:  2014-01-02

3.  IgG1 as a potential biomarker of post-chemotherapeutic relapse in visceral leishmaniasis, and adaptation to a rapid diagnostic test.

Authors:  Tapan Bhattacharyya; Armon Ayandeh; Andrew K Falconar; Shyam Sundar; Sayda El-Safi; Marissa A Gripenberg; Duncan E Bowes; Caroline Thunissen; Om Prakash Singh; Rajiv Kumar; Osman Ahmed; Osama Eisa; Alfarazdeg Saad; Sara Silva Pereira; Marleen Boelaert; Pascal Mertens; Michael A Miles
Journal:  PLoS Negl Trop Dis       Date:  2014-10-23

Review 4.  The immunology of post-kala-azar dermal leishmaniasis (PKDL).

Authors:  Eduard E Zijlstra
Journal:  Parasit Vectors       Date:  2016-08-23       Impact factor: 3.876

5.  Visceral Leishmaniasis IgG1 Rapid Monitoring of Cure vs. Relapse, and Potential for Diagnosis of Post Kala-Azar Dermal Leishmaniasis.

Authors:  Tegwen Marlais; Tapan Bhattacharyya; Om Prakash Singh; Pascal Mertens; Quentin Gilleman; Caroline Thunissen; Bruno C Bremer Hinckel; Callum Pearson; Bathsheba L Gardner; Stephanie Airs; Marianne de la Roche; Kiera Hayes; Hannah Hafezi; Andrew K Falconar; Osama Eisa; Alfarazdeg Saad; Basudha Khanal; Narayan Raj Bhattarai; Suman Rijal; Marleen Boelaert; Sayda El-Safi; Shyam Sundar; Michael A Miles
Journal:  Front Cell Infect Microbiol       Date:  2018-12-13       Impact factor: 5.293

Review 6.  Biomarkers in Post-kala-azar Dermal Leishmaniasis.

Authors:  Eduard E Zijlstra
Journal:  Front Cell Infect Microbiol       Date:  2019-07-31       Impact factor: 5.293

7.  Immune Responses in Post Kala-azar Dermal Leishmaniasis.

Authors:  Mitali Chatterjee; Ritika Sengupta; Debanjan Mukhopadhyay; Shibabrata Mukherjee; Aishwarya Dighal; Srija Moulik; Shilpa Sengupta
Journal:  Indian J Dermatol       Date:  2020 Nov-Dec       Impact factor: 1.494

8.  Utility of Blood as the Clinical Specimen for the Molecular Diagnosis of Post-Kala-Azar Dermal Leishmaniasis.

Authors:  Keerti Kaumudee Dixit; V Ramesh; Shreya Upadhyay; Abhishek Kumar Singh; Om Prakash Singh; Shyam Sundar; Ruchi Singh; Poonam Salotra
Journal:  J Clin Microbiol       Date:  2021-08-18       Impact factor: 5.948

9.  Prevalidation of an ELISA for Detection of a New Clinical Entity: Leishmania donovani-Induced Cutaneous Leishmaniasis.

Authors:  Bhagya Deepachandi; Sudath Weerasinghe; Himali Gunathilake; Thisira P Andrahennadi; Mahendra N Wickramanayake; Shantha Siri; Vishvanath Chandrasekharan; Preethi Soysa; Yamuna Siriwardana
Journal:  Int J Anal Chem       Date:  2020-07-15       Impact factor: 1.885

10.  In-situ immune profile of polymorphic vs. macular Indian Post Kala-azar dermal leishmaniasis.

Authors:  Ritika Sengupta; Shibabrata Mukherjee; Srija Moulik; Sneha Mitra; Surya Jyati Chaudhuri; Nilay Kanti Das; Uttara Chatterjee; Mitali Chatterjee
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2019-08-22       Impact factor: 4.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.